Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. There pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response
Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. There pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response
Recent Articles
- Arowana's Achievement: A Leading Force in Impact Investing
- Exploring AI Innovations Elevating Healthcare Efficiency
- CIRCA Scientific Launches Innovative CrossWise Access System
- Japan's Wage Growth and Yen Weakness Prompt BOJ Inflation Concerns
- Natera Reports Strong Growth in 2024 Revenue and Testing Volume
- FutureMain Enhances AI Predictive Maintenance in Middle East
- Standard Chartered Faces Sanctions Over Bond Mis-Selling Issues
- Goldman Sachs Adjusts Federal Rate Cut Predictions for 2025
- Caribou Biosciences Launches Phase 1 Trial for Lupus Therapy
- Exact Sciences Reports Strong Q4 2024 Revenue Growth
- China Medical University Dominates at Taiwan National Awards
- WuXi AppTec Commits to Sustainable Pharmaceutical Practices
- Rising Oil Prices as US Sanctions Impact Russian Exports
- Insignia Financial Ltd's Bidding War Escalates with Bain Capital
- Market Outlook: Earnings and Inflation Influence Stock Trends
- Celebrating Literary Excellence: PenCraft Book Awards 2024
- Challenges of Air Travel Growth in Achieving Climate Goals
- Cellectar Biosciences Unveils 2025 Strategic Vision
- Castle Biosciences Reports Strong Growth in 2024 Performance
- Telix Expands Its Pipeline with Acquisition of ImaginAb Assets
- Ascendis Pharma's Strategic Roadmap and Milestones for Growth
- Market Outlook: Job Data Fuels Bond Yields, Impacts Stocks
- Ascendis Pharma Unveils Strategic Roadmap for Future Growth
- Telix Pharmaceuticals Strengthens Position with Key Acquisition
- Innovative Retail Tech Recognized in Upcoming NRF Report
- Revvity's Upcoming Earnings Call and Positive Financial Outlook
- Vertex Pharmaceuticals Unveils Key Pipeline Developments Ahead of Meetings
- Class Action Lawsuit Against Capri Holdings Limited: Join Now
- Opportunity for Investors in Caribou Biosciences, Inc. Lawsuit
- Enhanced Offer by Bain Capital Targets Insignia Financial's Future
- Amicus Therapeutics Announces Unprecedented Revenue Growth
- Exelixis Reveals 2024 Financial Performance and 2025 Outlook
- Hologic Reports Strong Preliminary Revenues for Q1 of 2025
- Alnylam Pharmaceuticals Sets Ambitious Revenue Goals for 2025
- BioAge Labs, Inc. Faces Class Action Lawsuit Over Stock Decline
- Nextracker Investors Can Join Class Action for Loss Recovery
- Blueprint Medicines' Strategies for 2025 Success and Growth
- Class Action Lawsuit Opportunity for Regeneron Investors
- Capri Holdings Limited Investors Invited to Join Class Action
- Chancellor Scholz Addresses Tensions and Defense Spending Risks
- Scorpio Tankers Enhances Financial Flexibility with Bonds
- Investors Urged to Join Lawsuit Against Celsius Holdings, Inc.
- DMC Global Inc. Faces Securities Fraud Allegations from Investors
- Mark Cuban Highlights Bitcoin’s Value Amid Economic Challenges
- Peter Brandt's Insights on Bitcoin Price Movements Ahead
- Transforming Retail Technology: Direct Source at NRF 2025
- Molecular Partners Enhances Focus on Radiopharmaceuticals for Future Growth
- Expanding Horizons in Cancer Treatment: A New Era for DARPin Therapies
- QIAGEN's Strategic Plan: $300 Million Shareholder Return
- Innovative Dairy Farming: Transforming Waste into Energy